Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
Position Overview
Immunome is seeking a highly skilled Senior Research Scientist to serve as the Yeast Display Lead within the discovery organization. This hands-on, laboratory-based role will be responsible for establishing, owning, and advancing Immunome’s internal yeast display antibody discovery capabilities. The successful candidate will lead library design and construction, execute and optimize selection and screening strategies, and drive hit identification and downstream characterization efforts. This role offers a unique opportunity to shape a core antibody discovery platform and collaborate closely with discovery, translational, and preclinical teams.
Responsibilities
- Design, build, and optimize yeast display antibody libraries, including synthetic and immune-derived formats.
- Execute and oversee all stages of library construction, including cloning, transformation, expression assessment, and quality control.
- Plan, perform, and continuously improve MACS- and FACS-based selection strategies.
- Lead hit deconvolution using next-generation sequencing and sequence enrichment analyses.
- Conduct downstream characterization including expression testing, biophysical assays, and flow cytometry.
- Analyze complex datasets and communicate findings to cross-functional teams.
- Maintain detailed and accurate electronic laboratory notebooks.
- Collaborate across biology, protein engineering, chemistry, pharmacology, and translational teams.
Qualifications
- Bachelor’s degree with a minimum of 12 years of relevant experience; or Master’s degree with a minimum of 8 years; or Ph.D. with a minimum of 2 years of experience.
- Significant experience in drug discovery with deep expertise in yeast display technologies.
- Multiple years of hands-on experience in yeast display library construction, selections, and downstream characterization.
- Phage display experience is a plus.
- Advanced proficiency with Benchling and related data management systems.
Knowledge and Skills
- Subject matter expertise in yeast display and antibody discovery platforms.
- Strong analytical and data interpretation skills.
- Exceptional organizational and documentation skills.
- Excellent written and verbal communication skills.
- Ability to manage multiple projects in a fast-paced, collaborative environment.
Please note, the internal title for this role is Senior Research Associate, Yeast Display Lead
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
Similar Jobs
What We Do
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
